Summary & Overview
HCPCS Level II J2270: Injection, Morphine Sulfate, up to 10 mg
HCPCS Level II code J2270 denotes the injectable formulation of morphine sulfate, reported per unit of “up to 10 mg.” This code is clinically important across inpatient settings for acute pain management, anesthesia adjuncts, and perioperative analgesia. Nationally, accurate use of J2270 ensures consistent representation of administered opioid therapy on hospital claims and supports drug utilization tracking and reimbursement workflows.
Key payers included in this review are Aetna, Blue Cross Blue Shield, Cigna Health, and UnitedHealthcare. The publication outlines payer coverage patterns, common billing considerations, and clinical context for use in anesthesiology and inpatient hospital care. Readers will find a succinct explanation of the code’s clinical scope, guidance on distinguishing this code from related product-specific codes, and a summary of billing conventions that affect claim processing. Where specific data elements are not present in the input, the text notes that data is not available in the input.
This summary serves clinicians, coding professionals, and policy analysts who need a clear national overview of J2270’s purpose, typical use cases, and the payer landscape that influences claim adjudication and drug reporting in hospital settings.
Billing Code Overview
HCPCS Level II code J2270 represents the medication injection, morphine sulfate, up to 10 mg. This code is used to report administration of morphine sulfate as an injectable medication. The service type associated with this code is Anesthesiology, and the typical site of service is Inpatient Hospital (POS 21).
Clinical & Coding Specifications
Clinical Context
A hospitalized adult patient with acute severe pain (for example, postoperative pain, cancer-related pain, or severe flank pain) in an inpatient hospital setting (POS 21) requires parenteral opioid analgesia. The attending anesthesiologist or an emergency medicine physician evaluates the patient, documents indication and pain assessment, verifies allergies and opioid tolerance, and orders morphine sulfate for injection. Pharmacy dispenses morphine sulfate in vials labeled as non-preservative-free unless otherwise specified. Nursing administers the dose via intravenous push or infusion per facility protocol, documents dose and route, and records any discarded amount. The dose administered is up to 10 mg per injection event, consistent with HCPCS Level II code J2270 for billing. Common clinical workflow steps include order entry, pharmacy verification, bedside administration, monitoring for respiratory depression and analgesic effect, and documentation of administered dose and any waste.
Coding Specifications
-
HCPCS Level II code
J2270: Injection, morphine sulfate, up to 10 mg. -
Common modifiers and usage:
-
JW- Drug amount discarded/not administered to any patient -
Use when a portion of a single-use vial or prepared dose is discarded and the drug waste amount must be reported for reimbursement tracking.
-
59- Distinct Procedural Service -
Use when the injection service is distinct and separate from other services on the same day (e.g., separate encounter or unrelated procedure) to indicate it is not part of another billed service.
-
Associated provider taxonomies and specialties:
-
207L00000X- Anesthesiology -
207P00000X- Emergency Medicine Physician -
208D00000X- General Practice Physician
Related Diagnoses
-
R52- Pain, unspecified -
Clinical relevance: General indication for opioid analgesia when a specific pain diagnosis is not documented; supports use of parenteral morphine for acute pain control.
-
G89.3- Neoplasm related pain (acute) (chronic) -
Clinical relevance: Cancer-related pain often requires parenteral opioids for acute exacerbations or when oral therapy is inadequate; supports administration of morphine sulfate injection.
-
M54.5- Low back pain -
Clinical relevance: Acute severe low back pain may necessitate short-term parenteral opioid administration in the inpatient or emergency setting.
-
R07.9- Chest pain, unspecified -
Clinical relevance: When chest pain is assessed as non-cardiac musculoskeletal pain or other pain etiology, parenteral morphine may be administered for analgesia under monitoring.
-
R10.9- Unspecified abdominal pain -
Clinical relevance: Severe abdominal pain of unclear origin may prompt parenteral opioid administration for symptomatic control while diagnostic evaluation proceeds.
Related Codes
-
J2274- Use codeJ2274only for morphine sulfate that is labeled "preservative free." -
Relationship to
J2270:J2274is the preservative-free morphine sulfate counterpart. In clinical workflow,J2270is used for non-preservative-free morphine sulfate up to 10 mg;J2274is used instead when the product is specifically labeled preservative free. These codes are alternatives and are selected based on the drug formulation labeled on the vial.
National Reimbursement Benchmarks
National mean rates for HCPCS Level II code J2270 place Blue Cross Blue Shield above most payers at $3.63, while Medicare is at $2.00 and BUCA (the commercial average) is $2.92, making Medicare lower than the average commercial level. Aetna, Cigna Health, UnitedHealthcare, and BUCA cluster around the $2.53–$2.92 range, with Medicare at the low end.
Rate dispersion measured as the difference between the 75th and 25th percentiles is widest for Blue Cross Blue Shield (4.00 − 2.00 = 2.00) and moderate for BUCA (3.00 − 2.00 = 1.00). Aetna shows a smaller spread (2.33 − 2.00 = 0.33), and Cigna Health, UnitedHealthcare, and Medicare have no dispersion in the provided percentiles (0.00). The table and chart below present the full breakdown.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.